Statements (29)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
|
| gptkbp:activeIngredient |
gptkb:fedratinib
|
| gptkbp:approvalYear |
2019
|
| gptkbp:approvedBy |
gptkb:FDA
gptkb:EMA |
| gptkbp:ATCCode |
L01EL02
|
| gptkbp:CASNumber |
gptkb:936091-26-8
|
| gptkbp:chemicalFormula |
C27H36N6O3
|
| gptkbp:contraindication |
severe hepatic impairment
hypersensitivity to fedratinib |
| https://www.w3.org/2000/01/rdf-schema#label |
Inrebic
|
| gptkbp:indication |
gptkb:myelofibrosis
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:manufacturer |
gptkb:Bristol_Myers_Squibb
|
| gptkbp:mechanismOfAction |
JAK2 inhibitor
|
| gptkbp:pregnancyCategory |
Not recommended
|
| gptkbp:prescriptionStatus |
Rx-only
|
| gptkbp:PubChem_CID |
DB12933
|
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:sideEffect |
gptkb:anemia
nausea vomiting diarrhea fatigue increased liver enzymes thiamine deficiency |
| gptkbp:UNII |
2XJ0GDN2OQ
|
| gptkbp:bfsParent |
gptkb:fedratinib
|
| gptkbp:bfsLayer |
7
|